A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer.
Sahin U, Schuler M, Richly H, Bauer S, Krilova A, Dechow T, Jerling M, Utsch M, Rohde C, Dhaene K, Huber C, Türeci Ö.
Eur J Cancer. 2018 Sep;100:17-26. doi: 10.1016/j.ejca.2018.05.007. Epub 2018 Jun 21.
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm.
Nakamura Y, Kawazoe A, Lordick F, Janjigian YY, Shitara K.
Nat Rev Clin Oncol. 2021 Aug;18(8):473-487. doi: 10.1038/s41571-021-00492-2. Epub 2021 Mar 31.
What Therapeutic Biomarkers in Gastro-Esophageal Junction and Gastric Cancer Should a Pathologist Know About?
Kumarasinghe MP, Houghton D, Allanson BM, Price TJ.
Surg Pathol Clin. 2023 Dec;16(4):659-672. doi: 10.1016/j.path.2023.05.004. Epub 2023 Jun 23.
The Landscape and Prognosis of Microsatellite Stable (MSS) Esophageal, Gastro-Esophageal Junction and Gastric Adenocarcinomas with High Tumor Mutation Burden (TMB).
Voutsadakis IA.
Cancer Invest. 2024 Sep;42(8):697-709. doi: 10.1080/07357907.2024.2388107. Epub 2024 Aug 8.
"Gastro-Esophageal junction GIST".
Bhange SA, Sathe SM, Gala AP, Bhansali MS.
Indian J Cancer. 2015 Oct-Dec;52(4):510-2. doi: 10.4103/0019-509X.178390.
The complexity of cancer origins at the gastro-oesophageal junction.
Bornschein J, Quante M, Jansen M.
Best Pract Res Clin Gastroenterol. 2021 Mar-Apr;50-51:101729. doi: 10.1016/j.bpg.2021.101729. Epub 2021 Feb 14.
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.
Türeci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, Al-Batran SE, Wiechen K, Dhaene K, Maurus D, Gold M, Huber C, Krivoshik A, Arozullah A, Park JW, Schuler M.
Ann Oncol. 2019 Sep 1;30(9):1487-1495. doi: 10.1093/annonc/mdz199.
Chemoradiotherapy in tumours of the oesophagus and gastro-oesophageal junction.
Hulshof MC, van Laarhoven HW.
Best Pract Res Clin Gastroenterol. 2016 Aug;30(4):551-63. doi: 10.1016/j.bpg.2016.06.002. Epub 2016 Jun 25.
Current state of the art: immunotherapy in esophageal cancer and gastroesophageal junction cancer.
Li N, Sohal D.
Cancer Immunol Immunother. 2023 Dec;72(12):3939-3952. doi: 10.1007/s00262-023-03566-5. Epub 2023 Nov 23.
Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer.
Khan U, Shah MA.
Expert Opin Biol Ther. 2019 Nov;19(11):1135-1141. doi: 10.1080/14712598.2019.1656715. Epub 2019 Aug 27.
